NCT05377216

Brief Summary

Prospective cohort study evaluating the electrophysiologic and biochemical effects of stellate ganglion block in patients with ventricular tachycardia.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at P25-P50 for early_phase_1

Timeline
14mo left

Started Sep 2022

Longer than P75 for early_phase_1

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress76%
Sep 2022Jul 2027

First Submitted

Initial submission to the registry

May 2, 2022

Completed
15 days until next milestone

First Posted

Study publicly available on registry

May 17, 2022

Completed
4 months until next milestone

Study Start

First participant enrolled

September 1, 2022

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2027

Last Updated

November 21, 2025

Status Verified

November 1, 2025

Enrollment Period

4.8 years

First QC Date

May 2, 2022

Last Update Submit

November 20, 2025

Conditions

Ventricular Tachycardia

Outcome Measures

Primary Outcomes (1)

  • Ventricular Effective Refractory Period

    Change in Ventricular Effective Refractory Period at 600ms drive train (measured in milliseconds)

    30 minutes following stellate ganglion block

Secondary Outcomes (2)

  • Ventricular Arrhythmia Inducibility

    30 minutes following stellate ganglion block

  • Neuropeptide Y

    30 minutes following stellate ganglion block

Study Arms (1)

Stellate ganglion block

EXPERIMENTAL

All subjects will undergo stellate ganglion block during their VT ablation procedure

Drug: Stellate Ganglion Block

Interventions

Stellate Ganglion BlockDRUG

Left sided percutaneous stellate ganglion block

Stellate ganglion block

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Planned catheter based VT ablation
  • Age at least 18 years

You may not qualify if:

  • Pregnancy
  • Contraindication to SGB or VT ablation
  • Hypersensitivity of local anesthetic of amide type
  • Hemodynamic instability during the procedure prior to the study protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

RECRUITING

MeSH Terms

Conditions

Tachycardia, Ventricular

Condition Hierarchy (Ancestors)

TachycardiaArrhythmias, CardiacHeart DiseasesCardiovascular DiseasesCardiac Conduction System DiseasePathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Timothy Markman, MD

CONTACT

267-593-0103timothy.markman@pennmedicine.upenn.edu

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 2, 2022

First Posted

May 17, 2022

Study Start

September 1, 2022

Primary Completion (Estimated)

July 1, 2027

Study Completion (Estimated)

July 1, 2027

Last Updated

November 21, 2025

Record last verified: 2025-11

Locations

US(1)